胃苏颗粒联合兰索拉唑治疗活动性胃溃疡临床观察
|
摘要
目的:探讨胃苏颗粒联合兰索拉唑治疗活动性胃溃疡患者的临床效果。方法:选择2015年1月—2016年5月在医院进行活动性胃溃疡治疗的患者124例,按照随机数字的方法分为对照组和观察组,每组62例患者,对照组患者使用兰索拉唑进行治疗,观察组患者在对照组患者治疗方法基础上使用胃苏颗粒,对治疗效果进行对比。结果:两组患者在进行治疗后,溃疡底部厚苔面积,溃疡周围黏膜充血面积,溃疡周围再生上皮面积,幽门螺杆菌数值,活动性胃溃疡面积,患者的疼痛程度与患者的上腹痛,反酸,嗳气与胃灼热的症状评分数据均出现降低,观察组患者数据降低的幅度高于对照组患者,数据差异均具有统计学意义(P<0.05),观察组的治疗效果优于对照组,数据差异具有统计学意义(z=4.379,P<0.05),两组患者在治疗过程中的各项不良反应数据差异均不具有统计学意义(P>0.05)。结论:利用胃苏颗粒联合兰索拉唑的方法对活动性胃溃疡患者进行治疗,可以提升治疗效果,加快溃疡恢复程度,而且安全性较好,值得在临床范围内进行推广。
Objective:To investigate the clinical effect of Weisu Granules combined with lansoprazole in the treatment of patients with active gastric ulcer. Methods: A total of 124 patients with active gastric ulcer treated in our hospital from January 2015 to May 2016 were selected. According to the random number method,they were divided into control group and observation group,62 cases in each group. The control group was treated with Lansoprazole for treatment,and patients in the observation group were treated with Weisu Granule based on the treatment of the control group. The therapeutic effect was compared. Result: In the two groups after treatment,the ulcer area at the bottom of the thick fur,ulcer surrounding mucosa hyperemia around the ulcer area,epithelial regeneration area,numerical Helicobacter pylori,active gastric ulcer area,upper abdominal pain,pain and the patients' symptoms of acid reflux,heartburn and belching scores decreased. The observation group's data reduction was higher than that in the control group,and the differences were statistically significant( P < 0. 05). The treatment effect of the observation group was better than that of the control group,and the difference was statistically significant( z = 4. 379,P < 0. 05). There were no significant differences in the adverse reactions between the two groups during treatment( P > 0. 05). Conclusion: The method of Weisu Granules combined with lansoprazole in the treatment of patients with active gastric ulcer,can enhance the therapeutic effect,accelerate the recovery of the ulcer,and has good safety. It is worthy of promotion in the clinical range.
Objective:To investigate the clinical effect of Weisu Granules combined with lansoprazole in the treatment of patients with active gastric ulcer. Methods: A total of 124 patients with active gastric ulcer treated in our hospital from January 2015 to May 2016 were selected. According to the random number method,they were divided into control group and observation group,62 cases in each group. The control group was treated with Lansoprazole for treatment,and patients in the observation group were treated with Weisu Granule based on the treatment of the control group. The therapeutic effect was compared. Result: In the two groups after treatment,the ulcer area at the bottom of the thick fur,ulcer surrounding mucosa hyperemia around the ulcer area,epithelial regeneration area,numerical Helicobacter pylori,active gastric ulcer area,upper abdominal pain,pain and the patients' symptoms of acid reflux,heartburn and belching scores decreased. The observation group's data reduction was higher than that in the control group,and the differences were statistically significant( P < 0. 05). The treatment effect of the observation group was better than that of the control group,and the difference was statistically significant( z = 4. 379,P < 0. 05). There were no significant differences in the adverse reactions between the two groups during treatment( P > 0. 05). Conclusion: The method of Weisu Granules combined with lansoprazole in the treatment of patients with active gastric ulcer,can enhance the therapeutic effect,accelerate the recovery of the ulcer,and has good safety. It is worthy of promotion in the clinical range.
引文
[1]杨瑞琦,毛华,黄丽韫,等.铝碳酸镁联合艾司奥美拉唑治疗胃溃疡黏膜愈合质量的临床研究[J].中华消化杂志,2017,37(1):35-40.
[2]任建刚,贾道全.铝碳酸镁联合兰索拉唑治疗幽门螺旋杆菌相关性胃溃疡的临床疗效及安全性[J].临床和实验医学杂志,2015,1(9):767-769.
[3]Filkor K,Németh T,Nagy I,et al.The expression of inflammatory cytokines,TAM tyrosine kinase receptors and their ligands is upregulated in venous leg ulcer patients:a novel insight into chronic wound immunity[J].Int Wound J,2015,10(3):78-85.
[4]Laimas J,Gediminas K,Paulius S,et al.High rate of Helicobacter pylori reinfection in Lithuanian peptic ulcer patients[J].World Journal of Gastrointestinal Pathophysiology,2016,7(12):181-185.
[5]李霞,吴宏富.两种方案治疗幽门螺杆菌阳性活动性胃溃疡的临床效果比较[J].中国基层医药,2016,23(22):3400-3403.
[6]秦文燕,林琪,劳波,等.定标活检结合瘦素评价雷贝拉唑联合替普瑞酮对胃溃疡的疗效[J].医药导报,2017,36(9):993-996.
[7]周劲峰,叶婷婷,张昌林,等.克拉霉素、阿莫西林、兰索拉唑三联疗法联合瑞巴派特治疗老年消化性胃溃疡效果及对胃黏膜形态学的影响[J].中国老年学杂志,2015(21):6171-6173.
[8]范续,庄汝杰,王雨婷,等.佩戴肢具膝关节骨性关节炎患者VAS疼痛评分的临床研究[J].浙江临床医学,2016,18(5):832-833.
[9]中华人民共和国卫生部.中药新药临床研究指导原则[S].北京:中华人民共和国卫生部,1995:137-140.
[10]洪军波,汪安江,朱宏涛,等.272例残胃溃疡临床特征分析[J].中华消化杂志,2014(9):593-596.
[11]汤纳,姬滢,吴永斌,等.泮托拉唑和奥美拉唑治疗胃溃疡的疗效对比分析[J].中国生化药物杂志,2017(7):239-240,243.
[12]卢燕,刘丽凤,曾莎,等.前列腺干细胞抗原基因和磷脂酶CE1基因多态性与老年幽门螺旋杆菌感染胃溃疡的易感性及对临床预后的影响[J].中国老年学杂志,2015,35(17):4923-4925.
[13]孟华辉.埃索美拉唑在老年胃溃疡患者中的疗效及对胃蛋白酶原、c AMP、c GMP的影响观察[J].中国生化药物杂志,2017,37(2):220-222.
[14]李俊成,高建超.胃癌合并胃溃疡高危因素的临床分析[J].实用癌症杂志,2015,30(8):1227-1228,1233.
[15]赵丽伟,刘改芳,吴婧,等.质子泵抑制剂对糖尿病患者血糖的影响研究[J].陕西医学杂志,2017,46(4):419-421.
[16]李华,吴洪涛.法莫替丁与奥美拉唑钠治疗儿童消化性溃疡的效价比对比分析[J].广东医学,2017,38(z1):234-236.
[17]王娜,杨翠兰,伏新顺,等.香砂六君子汤加减联合兰索拉唑治疗脾胃虚弱型消化性溃疡疗效观察[J].陕西中医,2017,38(9):1187-1188.
[18]亓恒梁.奥美拉唑联合快胃片治疗非甾体抗炎药引起的胃溃疡疗效观察[J].中国当代医药,2013,20(9):113-114.
[19]张云操,杨世权.“中药竹医2号”治疗幽门螺杆菌相关性胃溃疡的临床观察[J].中成药,2016,38(11):2351-2354.
[20]倪春红,任婕,程井军,等.中西医结合治疗胃溃疡56例疗效观察[J].湖北中医药大学学报,2016,18(5):77-78.
[2]任建刚,贾道全.铝碳酸镁联合兰索拉唑治疗幽门螺旋杆菌相关性胃溃疡的临床疗效及安全性[J].临床和实验医学杂志,2015,1(9):767-769.
[3]Filkor K,Németh T,Nagy I,et al.The expression of inflammatory cytokines,TAM tyrosine kinase receptors and their ligands is upregulated in venous leg ulcer patients:a novel insight into chronic wound immunity[J].Int Wound J,2015,10(3):78-85.
[4]Laimas J,Gediminas K,Paulius S,et al.High rate of Helicobacter pylori reinfection in Lithuanian peptic ulcer patients[J].World Journal of Gastrointestinal Pathophysiology,2016,7(12):181-185.
[5]李霞,吴宏富.两种方案治疗幽门螺杆菌阳性活动性胃溃疡的临床效果比较[J].中国基层医药,2016,23(22):3400-3403.
[6]秦文燕,林琪,劳波,等.定标活检结合瘦素评价雷贝拉唑联合替普瑞酮对胃溃疡的疗效[J].医药导报,2017,36(9):993-996.
[7]周劲峰,叶婷婷,张昌林,等.克拉霉素、阿莫西林、兰索拉唑三联疗法联合瑞巴派特治疗老年消化性胃溃疡效果及对胃黏膜形态学的影响[J].中国老年学杂志,2015(21):6171-6173.
[8]范续,庄汝杰,王雨婷,等.佩戴肢具膝关节骨性关节炎患者VAS疼痛评分的临床研究[J].浙江临床医学,2016,18(5):832-833.
[9]中华人民共和国卫生部.中药新药临床研究指导原则[S].北京:中华人民共和国卫生部,1995:137-140.
[10]洪军波,汪安江,朱宏涛,等.272例残胃溃疡临床特征分析[J].中华消化杂志,2014(9):593-596.
[11]汤纳,姬滢,吴永斌,等.泮托拉唑和奥美拉唑治疗胃溃疡的疗效对比分析[J].中国生化药物杂志,2017(7):239-240,243.
[12]卢燕,刘丽凤,曾莎,等.前列腺干细胞抗原基因和磷脂酶CE1基因多态性与老年幽门螺旋杆菌感染胃溃疡的易感性及对临床预后的影响[J].中国老年学杂志,2015,35(17):4923-4925.
[13]孟华辉.埃索美拉唑在老年胃溃疡患者中的疗效及对胃蛋白酶原、c AMP、c GMP的影响观察[J].中国生化药物杂志,2017,37(2):220-222.
[14]李俊成,高建超.胃癌合并胃溃疡高危因素的临床分析[J].实用癌症杂志,2015,30(8):1227-1228,1233.
[15]赵丽伟,刘改芳,吴婧,等.质子泵抑制剂对糖尿病患者血糖的影响研究[J].陕西医学杂志,2017,46(4):419-421.
[16]李华,吴洪涛.法莫替丁与奥美拉唑钠治疗儿童消化性溃疡的效价比对比分析[J].广东医学,2017,38(z1):234-236.
[17]王娜,杨翠兰,伏新顺,等.香砂六君子汤加减联合兰索拉唑治疗脾胃虚弱型消化性溃疡疗效观察[J].陕西中医,2017,38(9):1187-1188.
[18]亓恒梁.奥美拉唑联合快胃片治疗非甾体抗炎药引起的胃溃疡疗效观察[J].中国当代医药,2013,20(9):113-114.
[19]张云操,杨世权.“中药竹医2号”治疗幽门螺杆菌相关性胃溃疡的临床观察[J].中成药,2016,38(11):2351-2354.
[20]倪春红,任婕,程井军,等.中西医结合治疗胃溃疡56例疗效观察[J].湖北中医药大学学报,2016,18(5):77-78.